Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Sarcoma 1CNS 1

Conditions

Melanoma 3

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × lorukafusp alfa × Dermatologic × Clear all
NCT03958383 2026-06-03

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

University of Wisconsin, Madison

Phase 1/2 Terminated
8 enrolled 12 charts
Dermatologic

Melanoma

NCT00590824 2019-11-21

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

University of Wisconsin, Madison

Phase 2 Completed
23 enrolled 22 charts
Dermatologic

Melanoma

NCT00109863 2019-11-19

Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma

University of Wisconsin, Madison

Phase 2 Completed
14 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡